AIHTA - Publications - Search - Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC)

Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC). Oncology Fact Sheet Nr. 108.

[thumbnail of Oncology Fact Sheet Nr.108.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
98kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WK Endocrine system > WK 200-300 Thyroid gland. Parathyroid gland
Language:English
Series Name:Oncology Fact Sheet Nr. 108
Deposited on:25 Aug 2022 14:43
Last Modified:25 Aug 2022 14:43

Repository Staff Only: item control page